Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-Human Dose-Escalation and Expansion Trial of GEN1053 (HexaBody-CD27) in Malignant Solid Tumors
2022-502419-12-00Phase 2Completed
- Sponsor
- Genmab
- Start
- Jan 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 3
01
Overview
Phase 2, open-label trial of GEN1053 in Non-hematologic malignancy, head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC) (2 arms), sponsored by Genmab. Primary endpoints: Dose-limiting toxicities and Adverse events and safety laboratory parameters. Started Jan 2023; status: completed.
02
Drugs
GEN1053
03
Conditions
Non-hematologic malignancyhead and neck squamous cell carcinoma (HNSCC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2022-502419-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502419-12-00.